Reasons for Treatment Changes in Patients With Moderate to Severe Psoriasis

被引:5
|
作者
Anderson, Kathryn L. [1 ]
Feldman, Steven R. [1 ,2 ,3 ]
机构
[1] Wake Forest Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC 27157 USA
[2] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC 27157 USA
[3] Wake Forest Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA
关键词
psoriasis; phototherapy; dermatology; TREATMENT PATTERNS; DRUG SURVIVAL; BIOLOGICS; DISCONTINUATION; POPULATION; ETANERCEPT; ADALIMUMAB; CARE; IMPAIRMENT; THERAPIES;
D O I
10.1177/1203475415572797
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Psoriasis treatment involves multiple treatment arms. Treatment choice depends on many factors and may change, due to the chronicity of psoriasis. Objective: The purpose of our study is to explore reasons for treatment changes in patients with moderate to severe psoriasis. Methods: Ten charts of patients with moderate to severe psoriasis were reviewed. The medication changes and reasons for change were extracted. A treatment change was defined as switching between medication classes, adding or removing a medication class, or switching medications within the oral or biologic medication class. Results: Seventy-seven treatment changes were identified. On average, I treatment change occurred per year of follow-up. The most common reason for treatment change was inadequate disease control. Conclusions: Inadequate disease control with current therapy is the most common reason a physician changes treatment for moderate to severe psoriasis. More efficacious treatments or ways to improve efficacy may help improve the long-term outcomes of psoriasis.
引用
收藏
页码:361 / 366
页数:6
相关论文
共 50 条
  • [41] Adalimumab treatment for moderate psoriasis reduces the risk of transitioning to severe psoriasis
    Papp, Kim
    Signorovitch, James
    Mulani, Parvzez
    Gupta, Shiraz
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB181 - AB181
  • [42] Biologic treatment sequences in moderate-to-severe psoriasis
    Ting, Samantha
    Lowe, Patricia
    Smith, Annika
    Fernandez-Penas, Pablo
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2024, 65 (07) : e178 - e186
  • [43] Drug focus: adalimumab in the treatment of moderate to severe psoriasis
    Vena, Gino A.
    Cassano, Nicoletta
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (02): : 93 - 103
  • [44] Role of topical therapy in the treatment of moderate to severe psoriasis
    Feldman, S
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB224 - AB224
  • [45] The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis
    Dapavo, Paolo
    Vujic, Igor
    Fierro, Maria Teresa
    Quaglino, Pietro
    Sanlorenzo, Martina
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (04) : 736 - 739
  • [46] EFFICIENCY OF BIOLOGIC AGENTS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS
    Blasco, A. J.
    Lazaro, P.
    Ferrandiz, C.
    Garcia-Diez, A.
    Liso, J.
    ACTAS DERMO-SIFILIOGRAFICAS, 2009, 100 (09): : 792 - 803
  • [47] Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis
    Papp, Kim A.
    Ho, Vincent
    Langley, Richard
    Lynde, Charles
    Poulin, Yves
    Shear, Neil
    Toole, John
    Zip, Catherine
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2005, 9 : 26 - 32
  • [48] Role of topical therapy in the treatment of moderate to severe psoriasis
    Feldman, S.
    EADV: Proceedings of the 15th Congress of the European Academy of Dermatology and Venereology, 2006, : 763 - 768
  • [49] Guselkumab for the treatment of moderate-to-severe plaque psoriasis
    Yang, Eric J.
    Sanchez, Isabelle M.
    Beck, Kristen
    Sekhon, Sahil
    Wu, Jashin J.
    Bhutani, Tina
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 333 - 344
  • [50] Effects of methotrexate and etanercept treatment in moderate and severe psoriasis
    Benites, Elizabeth
    Carrillo, Esmeralda
    Heras, Martha
    MEDICINE, 2022, 101 (45) : E31527